IMU Stock Overview
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Imugene Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.078 |
| 52 Week High | AU$0.19 |
| 52 Week Low | AU$0.039 |
| Beta | 3.21 |
| 1 Month Change | -25.71% |
| 3 Month Change | -25.71% |
| 1 Year Change | -42.22% |
| 3 Year Change | -58.95% |
| 5 Year Change | 358.82% |
| Change since IPO | 680.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMU | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -14.8% | -3.0% | -2.2% |
| 1Y | -42.2% | -9.0% | 4.5% |
Return vs Industry: IMU underperformed the Australian Biotechs industry which returned -9% over the past year.
Return vs Market: IMU underperformed the Australian Market which returned 4.5% over the past year.
Price Volatility
| IMU volatility | |
|---|---|
| IMU Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: IMU's share price has been volatile over the past 3 months.
Volatility Over Time: IMU's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | n/a | Leslie Chong | www.imugene.com |
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company’s HER-Vaxx is in phase 2 study for gastric cancer.
Imugene Limited Fundamentals Summary
| IMU fundamental statistics | |
|---|---|
| Market cap | AU$570.95m |
| Earnings (TTM) | -AU$89.24m |
| Revenue (TTM) | AU$15.03m |
34.6x
P/S Ratio-5.8x
P/E RatioIs IMU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMU income statement (TTM) | |
|---|---|
| Revenue | AU$15.03m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$15.03m |
| Other Expenses | AU$104.27m |
| Earnings | -AU$89.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 100.00% |
| Net Profit Margin | -593.63% |
| Debt/Equity Ratio | 0% |
How did IMU perform over the long term?
See historical performance and comparison